Search the Newsreel

Vistagen Therapeutics Releases Q1 2027 Financial Results

Vistagen Therapeutics reported a narrower loss for Q1 fiscal 2027, with a basic and diluted loss of $0.30 per share and a net loss of $13.0M. The company saw a significant revenue increase to $1.5M, up 504.9% year-over-year, as it continues to develop therapies …

Volkswagen (XTRA:VOW3) Could Be 31% Below Fair Value After US Push Reports

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Volkswagen (XTRA:VOW3) is back in focus after reports it will appoint outgoing Audi sales chief Marco Schubert to lead its US business, with a fresh push into …

HSBC Stock And 2 Global Bank Picks for Trade and Rate Rule Changes

This article identifies three global banking stocks—Banco Bilbao Vizcaya Argentaria (BBVA), Banco Santander (SAN), and HSBC Holdings (HSBA)—that are well-positioned to navigate the evolving landscape of trade, interest rates, and compliance regulations. These banks offer diversified operations, significant digital banking investments, and varying risk-reward …

Highbridge Capital (AXIN) discloses 9.1% holding in Axiom Intelligence Class A

Cathay General Bancorp (CATY) Could Be Fully Valued After Fresh Growth And Capital Concerns

New analysis suggests Cathay General Bancorp (CATY) may be fully valued despite a recent share price surge and a narrative of being "30% undervalued" by analysts. Concerns include lagging net interest income, earnings growth, and expectations for soft capital generation. The bank's reliance on …

Vistagen Reports Narrower Q1 Loss; Plans FDA Meeting On Fasedienol Development Path

(RTTNews) - Vistagen Therapeutics Inc. (VTGN), a late clinical-stage biopharmaceutical company developing intranasal pherine therapies for neuropsychiatric and other disorders, reported first quarter fiscal 2027 results and provided a corporate update. Vistagen is developing rapid-onset intranasal pherine product candidates designed to target nose-to-brain neurocircuitry. …

Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice

Urogen Pharma (URGN) is highlighted as a strong momentum pick due to its "A" Momentum Style Score from Zacks and a Zacks Rank of #2 (Buy). The article details URGN's impressive short-term and long-term price performance, outperforming both its industry and the S&P 500. …

Why Is General Motors Resuming EV Battery Production in Ohio?

General Motors is set to restart battery cell production at its Ultium Cells facility in Warren, Ohio, after a seven-month shutdown due to weaker EV demand. This joint venture with LG Energy Solution will resume operations next week with an expected 1,400 employees, producing …

GenSight Biologics S.A.: Objectif de Cours et Consensus des Analystes | SIGHT | FR0013183985

argenx SE: Objectif de Cours et Consensus des Analystes | ARGX | NL0010832176

Genesis Energy (GEL) On Fresh Earnings And Buyback Progress Still Looks Hard To Value

Argenx stock steadies after Forte Biosciences deal and post-earnings pullback

Argenx stock is consolidating after a strong Q2 2026 earnings beat and a significant $2.2 billion acquisition of Forte Biosciences. Despite a recent pullback, the stock remains in positive territory year-to-date, with analysts maintaining a constructive outlook and an implied upside of roughly 23% …

General Fusion Group Ltd. Cl A (NASDAQ: GFUZ) Stock Price, News & Analysis

This page provides an overview of General Fusion Group Ltd. Cl A (NASDAQ: GFUZ) stock, including its current price, basic financial fundamentals, and a chart from TradingView. It also offers access to various Kalkine research reports and tools. The article highlights the stock's performance …

Armistice Capital (MGNX) discloses 5.0M-share MacroGenics position in 13G/A

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 5,006,752 shares of MacroGenics, Inc. common stock, which represents 7.88% of the outstanding class. Both Armistice Capital, as investment manager, and Steven Boyd, as its managing member, hold shared voting and dispositive …

GENESYS: Q1 FY27 saw revenue growth, new leadership, and a major Rights Issue announcement

GrowGeneration Beats on Q2 Earnings, Hikes '26 Adjusted EBITDA View

GrowGeneration (GRWG) reported a narrower Q2 2026 loss of 3 cents per share, surpassing the Zacks Consensus Estimate. The company also saw a 5.5% year-over-year sales increase to $43.2 million and raised its full-year adjusted EBITDA outlook to $2-$3 million. This positive performance was …

Repligen Corp (RGEN) stake at 3.1% in new T. Rowe Price 13G/A

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G/A, reporting a 3.1% beneficial ownership stake in Repligen Corp (RGEN), totaling 1,751,887 shares of common stock as of June 30, 2026. The filing indicates sole voting power over 1,744,549 shares and sole dispositive …

10x Genomics (TXG) Q2 2026 Earnings Call Transcript

Analysts Offer Insights on Materials Companies: Franco-Nevada (FNV) and Lithium Argentina (LAR)

Genie Energy Earnings Jump Y/Y in Q2 on Margin Expansion

Intelligent Bio Solutions (INBS) gets 5.91% ownership update from Armistice Capital

Armistice Capital, LLC and Steven Boyd have filed an amended passive ownership report for Intelligent Bio Solutions Inc. (INBS), disclosing a beneficial ownership of 141,397 shares, which represents 5.91% of the common stock. All shares are held with shared voting and dispositive power. Armistice …

Armistice Capital (EVGN) discloses 4.99% beneficial stake in Evogene shares

Armistice Capital, LLC and Steven Boyd have reported a 4.99% beneficial ownership stake in Evogene Ltd. (EVGN) through an amended Schedule 13G filing. This amounts to 713,539 ordinary shares, which are directly held by Armistice Capital Master Fund Ltd. The filing clarifies that Armistice …

Dow Movers: AMGN, HONIV

In early trading on Friday, shares of Honeywell International topped the list of the day's best performing Dow Jones Industrial Average components, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain. And the worst performing Dow component thus far on the …

Wall Street Analysts Believe Generac Holdings (GNRC) Could Rally 31.51%: Here's is How to Trade

Generac Holdings (GNRC) closed the last trading session at $216.66, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target …

Allogene Therapeutics (ALLO) Income Statement & Earnings

UBS Adjusts PT on Cogent Communications to $11 From $17, Maintains Neutral Rating

UBS has lowered its price target for Cogent Communications (CCOI) to $11 from $17, while maintaining a Neutral rating on the stock. This adjustment reflects a revised outlook for the integrated telecommunications services provider. The company's stock is currently trading at $10.90, down -49.44% …

NexGen Energy begins construction on its first uranium mine in Saskatchewan

NexGen Energy Ltd. has started construction on its $2.2 billion Rook I uranium mine project in northern Saskatchewan. The project, located on the southern end of the Athabasca Basin, is expected to take four years to build and will eventually produce 30 million pounds …

Implied Volatility Surging for Banco Bilbao Stock Options

Implied volatility for Banco Bilbao Vizcaya Argentaria, S.A. (BBVA) stock options, particularly the Sept. 18, 2026 $25.00 Call, is surging, indicating that the market anticipates a significant price movement. Despite this, analysts currently rate Banco Bilbao as a Zacks Rank #4 (Sell), suggesting a …

Genting Singapore (SGX:G13) Stock Rally Meets Shrinking Earnings Power

Ultragenyx (RARE): RTW Investments and Roderick Wong report 7.9% stake

RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 7.9% in Ultragenyx Pharmaceutical Inc., totaling 7,796,895 shares. This disclosure, made via a Schedule 13G filing, indicates shared voting and dispositive power over these shares, which are held by funds advised …

Vistagen reports Q1 FY2027: $1.48M revenue, $13.0M net loss, $31.7M cash at June 30, 2026

Vistagen announced its Q1 FY2027 results, reporting $1.476 million in revenue and a net loss of $13.03 million. The company ended the quarter with $31.7 million in cash, expecting these funds to support operations into 2027. Vistagen also highlighted upcoming FDA discussions regarding a …

Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com

This article announces that VistaGen Therapeutics Inc. has filed a Form 8K on August 14th. The brief news item from Investing.com provides no further details about the content of the filing but notes the stock symbol VTGN.

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Vistagen announced its fiscal year 2027 first-quarter financial results, highlighting progress in its fasedienol program for social anxiety disorder, including plans for FDA engagement regarding a Phase 3 pathway. The company reported a net loss of $13.0 million, reduced R&D and G&A expenses due …

VistaGen Therapeutics GAAP EPS of -$0.30 beats by $0.06, revenue of $1.48M beats by $1.31M

* VistaGen Therapeutics press release [https://seekingalpha.com/pr/20619736-vistagen-reports-fiscal-year-2027-first-quarter-financial-results-and-corporate-update] (VTGN [https://seekingalpha.com/symbol/VTGN]): Q1 GAAP EPS of -$0.30 beats by $0.06. * Revenue of $1.48M (+516.7% Y/Y) beats by $1.31M. * Cash, cash equivalents, and marketable securities were $31.7 million as of June 30, 2026. Based on current operating …

Gentex Corp (NASDAQ:GNTX): A Sustainable Dividend for Quality-Focused Investors

Q3 Earnings Forecast for Neurogene Issued By HC Wainwright